ClinicalTrials.gg
Active, not recruitingNCT05789069Updated Jun 8, 2026

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

A Phase 1 interventional study of HFB200603 and Tislelizumab in Renal Cell Carcinoma, Melanoma and Non Small Cell Lung Cancer, sponsored by HiFiBiO Therapeutics. Active, not recruiting at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by HiFiBiO Therapeutics · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
83
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 164 studies in Carcinoma, Renal Cell with a site in Spain — 25 open to participants now, 51 under way, 14 of them phase 3. Carcinoma, Renal Cell · Spain.

Planned enrollment
106th of 139
83 · median 223
Started
2023
with 8 others
Phase 1
40 of 164
9 open now
Primary completion
2026-12
later than 20 of 50 live
Registered
143rd of 164
by date

Among the 164 studies in Carcinoma, Renal Cell with a site in Spain, this one is the 106th largest by planned enrollment of the 139 interventional ones that give a count, is one of 9 that started in 2023, is one of 40 in phase 1, reaches primary completion later than 20 of the 50 other live ones, and was the 143rd registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

25 of the 164 studies in Carcinoma, Renal Cell with a site in Spain are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Carcinoma, Renal Cell with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to test the safety and tolerability of HFB200603 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses of HFB200603 as a monotherapy or in combination with tislelizumab until a safe and tolerable dose of HFB200603 as a single agent or combination therapy is determined. During the expansion part, participants will take the doses of HFB200603 as a monotherapy (optional arm) or in combination with tislelizumab that were determined from the escalation part of the study and will be assigned to a group based on the type of cancer the participants have.

Read the detailed description

This is a Phase 1a/b, first in human, open-label, dose escalation and expansion study in adults with advanced cancers. The study will comprise of

  1. A Screening Period of up to 28 days
  2. A Treatment Period during which participants will receive the study drug on the first day of each cycle where each cycle is 21 days. Number of cycles depends on how the disease responds to the study drug
  3. A Follow-up Period which involves 2 visits
03

Conditions studied

  • Renal Cell Carcinoma
  • Melanoma
  • Non Small Cell Lung Cancer
  • Gastric Cancer
  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must have one of the following cancers and previously received the following for the advanced/ disease:

    • Renal cell carcinoma: at least 2 lines of therapy
    • Non-small cell lung cancer: at least 2 lines of therapy
    • Melanoma:

      • BRAF V600E positive: must have received at least 2 lines of therapy
      • BRAF V600E negative: must have received at least 1 line of therapy
    • Gastric cancer: at least 1 line of therapy
    • Colorectal cancer: at least 3 lines of therapy
  • Suitable site to at pre-treatment and on-treatment
  • as determined by (RECIST) 1.1
  • performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Systemic anti-cancer therapy within 2 weeks prior to start of study drug or within 4 weeks for immune-oncologic therapy. For cytotoxic agents with major delayed toxicity (e.g., mitomycin C), 6 weeks of washout are mandated.
  • Therapeutic radiation therapy within the past 2 weeks
  • Active diseases or history of autoimmune disease that may relapse
  • Any ≤ 5 years before first dose of study drug except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively
  • Systemic therapy (>10 mg/day of prednisone or equivalent) or any immune suppressive medication ≤ 14 days before first dose
  • Patients with toxicities (as a result of prior anticancer therapy) which have not recovered to baseline or stabilized, except for adverse events not considered a likely safety risk (e.g., alopecia, neuropathy, and specific laboratory abnormalities)
  • Severe or unstable medical condition, including uncontrolled diabetes, coagulopathy, or unstable psychiatric condition
  • Major surgery within 28 days of the first dose of study drug
  • History of interstitial lung disease, non-infectious pneumonitis, or uncontrolled lung diseases including pulmonary fibrosis or acute lung diseases. For combination only: non-small cell lung cancer patients, or patients with significantly impaired pulmonary function or who require supplemental oxygen at baseline must undergo an assessment of pulmonary function at screening
  • History of allergic reactions, immune related reactions, or cytokine release syndrome (CRS) attributed to compounds of similar chemical or biologic composition to monoclonal antibodies or any of HFB200603 or tislelizumab
  • For combination only: Prior randomization in a tislelizumab study regardless of the treatment arm, until the primary and key secondary endpoints of the study have read out
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
83 participants (estimated)

Study arms

  • Experimental
    Dose Escalation - HFB200603 monotherapy

    Participants will be administered HFB200603 at dose levels 1-4 as an intravenous infusion to determine the Recommended Dose for Expansion (RDE).

    Drug: HFB200603

  • Experimental
    Dose Escalation - HFB200603 in combination with tislelizumab

    Participants will be administered HFB200603 at dose levels 1-3 in combination with one dose level of tislelizumab as an intravenous infusion to determine the combination Recommended Doses for Expansion (RDEs).

    Drug: HFB200603 · Drug: Tislelizumab

  • Experimental
    Dose Expansion - HFB200603 monotherapy (optional)

    Participants will be administered HFB200603 at monotherapy RDE as an intravenous infusion.

    Drug: HFB200603

  • Experimental
    Dose Expansion - HFB200603 in combination with tislelizumab

    Participants will be administered HFB200603 in combination with tislelizumab at combination RDEs as an intravenous infusion. Based on the cancer type, participants will be randomized to combination HFB200603 RDE 1 or RDE 2.

    Drug: HFB200603 · Drug: Tislelizumab

Interventions

  • DrugHFB200603

    Participants will be administered HFB200603 as described in the experimental arm.

  • Participants will be administered tislelizumab as described in the experimental arm.

    Also known as: BGB-A317

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs) meeting protocol-defined Dose-Limiting Toxicity (DLT) criteria during Dose Escalation

    Severity of adverse events will be based on common terminology criteria for adverse events (CTCAE) version 5.0

    Time frame: The first cycle of treatment (Day 1 up to Day 21)

  2. Number of participants with AEs

    Severity of AEs will be assessed based on CTCAE version 5.0 (except for cytokine release syndrome which will be assessed by American Society for Transplantation and Cellular Therapy grading)

    Time frame: Cycle 1 Day 1 to 90 days after the last dose of study drug(s) (each cycle is 21 days), assessed up to 3 years

  3. Number of participants with changes in laboratory values

    Time frame: Cycle 1 Day 1 to 90 days after the last dose of study drug(s) (each cycle is 21 days), assessed up to 3 years

  4. Number of participants with changes in vital signs

    Time frame: Cycle 1 Day 1 to 90 days after the last dose of study drug(s) (each cycle is 21 days), assessed up to 3 years

  5. Number of participants with changes in electrocardiogram (ECG)

    Time frame: Cycle 1 Day 1 to 90 days after the last dose of study drug(s) (each cycle is 21 days), assessed up to 3 years

  6. Number of participants with changes in tolerability (dose interruptions and dose intensity)

    Time frame: Cycle 1 Day 1 to 90 days after the last dose of study drug(s) (each cycle is 21 days), assessed up to 3 years

  7. To determine a Recommended Phase 2 Dose (RP2D) during Dose Expansion

    Time frame: Cycle 1 Day 1 to 90 days after the last dose of study drug(s) (each cycle is 21 days), assessed up to 3 years

Secondary outcomes

  1. Objective Response Rate (ORR) as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune-RECIST (iRECIST)

    Time frame: Baseline to 90 days after the last dose of study drug(s) (each cycle is 21 days), assessed up to 3 years

  2. Disease Control Rate (DCR) as determined by RECIST 1.1 and iRECIST

    Time frame: Baseline to 90 days after the last dose of study drug(s) (each cycle is 21 days), assessed up to 3 years

  3. Duration of Response (DOR) as determined by RECIST 1.1 and iRECIST

    Time frame: Start of first response to first date of disease progression, clinical progression or death, whichever occurs first, assessed up to 3 years

  4. Progression Free Survival (PFS) as determined by RECIST 1.1 and iRECIST

    Time frame: Baseline to disease progression or death, whichever occurs first, assessed up to 3 years

  5. Minimum serum concentration (Cmin)

    Time frame: Cycle 1 Day 1 to day of the last dose of study drug(s) (each cycle is 21 days), through study completion, an average of 3 year

  6. Maximum serum concentration (Cmax)

    Time frame: Cycle 1 Day 1 to day of the last dose of study drug(s) (each cycle is 21 days), through study completion, an average of 3 year

  7. Area under the concentration versus time curve (AUC)

    Time frame: Cycle 1 Day 1 to day of the last dose of study drug(s) (each cycle is 21 days), through study completion, an average of 3 year

  8. Terminal half-life (T1/2)

    Time frame: Cycle 1 Day 1 to day of the last dose of study drug(s) (each cycle is 21 days), through study completion, an average of 3 year

  9. Serum concentration for measurement of anti-HFB200603 antibodies

    Time frame: Cycle 1 Day 1 to day of the last dose of study drug(s) (each cycle is 21 days), through study completion, an average of 3 year

07

Study locations

11 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Dec 2026, 43 months after the start.

Of 139 industry-sponsored phase 1 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 43 months is below that.

Counting every sponsor, half of 221 studies reached it within 50 months; a quarter within 32 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2023
First posted
Mar 29, 2023
StartActual
May 9, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05789069
Lead sponsor
HiFiBiO Therapeutics
Responsible party
Sponsor
First posted
Mar 29, 2023
Start date
May 9, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 8, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion